EBS
Emergent BioSolutions Inc.Company with tickers: EBS
Market Cap
$434.96M
Shares Outstanding
51,596,296
CIK
1367644
CUSIP
29089Q105
13F Activity (30d)
4 filings
3 filers
Website
Visit website
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$50,000,000
as of 2026-02-28
Remaining Authorization
$46,500,000
as of 2026-03-31
Program Utilization
7.0%
$3,500,000 used of $50,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-03-31 YTD | $9,000,000 | 10-Q, filed 2026-05-01 | ||
| 2025-12-31 | $24,900,000 | 10-K, filed 2026-02-27 | ||
| 2024-12-31 | $0 | 10-K, filed 2026-02-27 | ||
| 2023-12-31 | $0 | 10-K, filed 2026-02-27 | ||
| 2022-12-31 | $82,100,000 | 10-K, filed 2025-03-04 | ||
| 2021-12-31 | $106,000,000 | 10-K, filed 2024-03-08 | ||
| 2020-12-31 | $0 | 10-K/A, filed 2023-12-11 | ||
| 2019-12-31 | $0 | 10-K, filed 2022-02-25 | ||
| 2018-12-31 | $100,000 | 10-K, filed 2021-02-19 | ||
| 2017-12-31 | $33,100,000 | 10-K, filed 2020-02-25 | ||
| 2016-12-31 | $0 | 10-K, filed 2019-02-22 | ||
| 2015-12-31 | $100,000 | 10-K, filed 2018-02-23 | ||
| 2014-12-31 | $200,000 | 10-K, filed 2017-02-28 | ||
| 2013-12-31 | $213,000 | 10-K, filed 2016-02-29 | ||
| 2012-12-31 | $5,906,000 | 10-K, filed 2015-03-09 | ||